LivaNova PLC (LIVN) stock
LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 13/3032% above fair value
$94.54+2.62 (+2.85%)
Close on Nov 18, 2026Market cap $5.21BP/E 27.9Yield –
LivaNova r&d expenses
Research and development expenses are spending on new products and technology.
LivaNova's R&D Expenses for the twelve months ending Jun 30, 2026 was $213.06M, up 20.3% year over year. For fiscal 2025 it was $185.76M, up 1.8% from the year before. Over ten years it grew 15.2% a year on average. The highest annual figure on record is $193.82M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.76M | +1.8% |
| FY2024 | Dec 31, 2024 | $182.51M | -5.8% |
| FY2023 | Dec 31, 2023 | $193.82M | +24.4% |
| FY2022 | Dec 31, 2022 | $155.81M | -15.1% |
| FY2021 | Dec 31, 2021 | $183.41M | +20.0% |
| FY2020 | Dec 31, 2020 | $152.90M | +4.1% |
| FY2019 | Dec 31, 2019 | $146.85M | +0.6% |
| FY2018 | Dec 31, 2018 | $145.95M | +33.3% |
| FY2017 | Dec 31, 2017 | $109.52M | +159.2% |
| FY2015 | Apr 24, 2015 | $42.25M | -6.6% |
| FY2014 | Apr 25, 2014 | $45.22M | +8.8% |
| FY2013 | Apr 26, 2013 | $41.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $53.66M | +13.7% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $58.70M | +55.0% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $52.12M | +20.4% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $48.58M | -0.5% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $47.19M | +5.5% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $37.88M | -17.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $43.31M | -6.2% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $48.81M | +4.9% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $44.74M | -12.5% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $45.66M | -8.6% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $46.17M | +2.7% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $46.54M | +30.3% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $51.12M | +49.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $49.99M | +22.2% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $44.93M | +1.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $35.73M | -15.2% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $34.23M | -34.9% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $40.92M | -8.3% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $44.10M | -0.9% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $42.13M | -11.1% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $52.56M | +109.0% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $44.63M | +24.3% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $44.48M | +94.9% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $47.37M | +3.2% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $25.15M | -27.2% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $35.90M | -17.6% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $22.83M | -39.2% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $45.90M | +8.2% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $34.54M | +1.0% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $43.58M | +37.2% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $37.56M | +16.0% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $42.42M | +85.2% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $34.22M | +1.1% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $31.75M | +55.8% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $32.39M | +203.1% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $22.90M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $33.83M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $20.39M | – |
| Q4 FY2015CQ1 2015 | Apr 24, 2015 | $10.69M | – |
See a number that looks wrong?